Luca Mariotta

Luca Mariotta

Auto-generated profile, based on publicly available information

Luca Mariotta

Swiss Stem Cell Foundation, 6900 Lugano, Switzerland

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2009 in Pflügers Archiv - European Journal of Physiology
Verified
Journal Article
Closed access
FVFrançois Verrey
François Verrey
DSDustin Singer
Dustin Singer
TRTamara Ramadan
Tamara Ramadan
RVRaphael Vuille-dit-Bille
Raphael Vuille-dit-Bille
LMLuca Mariotta
Luca Mariotta
SCSimone M. R. Camargo
Simone M. R. Camargo

15 September 2012 in American Journal of Physiology-Gastrointestinal and Liver Physiology
Verified
Journal Article
Closed access
PDF file
DSDustin Singer
Dustin Singer
SCSimone M. R. Camargo
Simone M. R. Camargo
TRTamara Ramadan
Tamara Ramadan
MSMatthias Schäfer
Matthias Schäfer
LMLuca Mariotta
Luca Mariotta
FVFrançois Verrey
François Verrey
Mutations in the main intestinal and kidney luminal neutral amino acid transporter B0AT1 (Slc6a19) lead to Hartnup disorder, a condition that is characterized by neutral aminoaciduria and in some cases pellagra-like symptoms. These latter symptoms caused by low-niacin are thought to result from defective intestinal absorption of its precursor l-tryptophan. Since Ace2 is necessary for intestinal B0AT1 expression, we tested the impact of intestinal B0AT1 absence in ace2 null mice. Their weight gain following weaning was decreased, and Na+-dependent uptake of B0AT1 substrates measured in everted intestinal rings was defective. Additionally, high-affinity Na+-dependent transport of l-proline, presumably via SIT1 (Slc6a20), was absent, whereas glucose uptake via SGLT1 (Slc5a1) was not affected. Measurements of small intestine luminal amino acid content following gavage showed that more l-tryptophan than other B0AT1 substrates reach the ileum in wild-type mice, which is in line with its known lower apparent affinity. In ace2 null mice, the absorption defect was confirmed by a severalfold increase of l-tryptophan and of other neutral amino acids reaching the ileum lumen. Furthermore, plasma and muscle levels of glycine and l-tryptophan were significantly decreased in ace2 null mice, with other neutral amino acids displaying a similar trend. A low-protein/low-niacin diet challenge led to differential changes in plasma amino acid levels in both wild-type and ace2 null mice, but only in ace2 null mice to a stop in weight gain. Despite the combination of low-niacin with a low-protein diet, plasma niacin concentrations remained normal in ace2 null mice and no pellagra symptoms, such as photosensitive skin rash or ataxia, were observed. In summary, mice lacking Ace2-dependent intestinal amino acid transport display no total niacin deficiency nor clear pellagra symptoms, even under a low-protein and low-niacin diet, despite gross amino acid homeostasis alterations.

1 October 2014 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
SCSimone M. R. Camargo
Simone M. R. Camargo
RVRaphael Vuille-dit-Bille
Raphael Vuille-dit-Bille
LMLuca Mariotta
Luca Mariotta
TRTamara Ramadan
Tamara Ramadan
KHKatja Huggel
Katja Huggel
FVFrançois Verrey
François Verrey
Levodopa (L-DOPA) is the naturally occurring precursor amino acid for dopamine and the main therapeutic agent for neurologic disorders due to dopamine depletion, such as Parkinson’s disease. l-DOPA absorption in small intestine has been suggested to be mediated by the large neutral amino acids transport machinery, but the identity of the involved transporters is unknown. Clinically, coadministration of l-DOPA and dietary amino acids is avoided to decrease competition for transport in intestine and at the blood-brain barrier. l-DOPA is routinely coadministered with levodopa metabolism inhibitors (dopa-decarboxylase and cathechol-O-methyl transferase inhibitors) that share structural similarity with levodopa. In this systematic study involving Xenopus laevis oocytes and Madin-Darby canine kidney epithelia expression systems and ex vivo preparations from wild-type and knockout mice, we identified the neutral and dibasic amino acids exchanger (antiporter) b0,+AT-rBAT (SLC7A9-SLC3A1) as the luminal intestinal l-DOPA transporter. The major luminal cotransporter (symporter) B0AT1 (SLC6A19) was not involved in levodopa transport. L-Leucine and L-arginine competed with levodopa across the luminal enterocyte membrane as expected for b0,+AT-rBAT substrates, whereas dopa-decarboxylase and cathechol-O-methyl transferase inhibitors had no effect. The presence of amino acids in the basolateral compartment mimicking the postprandial phase increased transepithelial levodopa transport by stimulating basolateral efflux via the antiporter LAT2-4F2 (SLC7A8-SLC3A2). Additionally, the aromatic amino acid uniporter TAT1 (SLC16A10) was shown to play a major role in l-DOPA efflux from intestinal enterocytes. These results identify the molecular mechanisms mediating small intestinal levodopa absorption and suggest strategies for optimization of delivery and absorption of this important prodrug.

12 November 2012 in The Journal of Physiology
Verified
Journal Article
Open access
PDF file
LMLuca Mariotta
Luca Mariotta
TRTamara Ramadan
Tamara Ramadan
DSDustin Singer
Dustin Singer
AGAdriano Guetg
Adriano Guetg
BHBrigitte Herzog
Brigitte Herzog
FVFrançois Verrey
François Verrey
Key points: The amino acid (AA) transporter TAT1 (Slc16A10) mediates facilitated diffusion of aromatic AAs (AAAs) across membranes. TAT1 null mice lack liver control of AAAs and display altered epithelial AA transport. The data support the hypothesis that equilibrative transport of essential AAs by TAT1 is crucial for body AA homeostasis control. Abstract  The uniporter TAT1 (Slc16a10) mediates the facilitated diffusion of aromatic amino acids (AAAs) across basolateral membranes of kidney, small intestine and liver epithelial cells, and across the plasma membrane of non‐epithelial cells like skeletal myocytes. Its role for body AA homeostasis has now been investigated using newly generated TAT1 (Slc16a10) defective mice (tat1−/−). These mice grow and reproduce normally, show no gross phenotype and no obvious neurological defect. Histological analysis did not reveal abnormalities and there is no compensatory change in any tested AA transporter mRNA. TAT1 null mice, however, display increased plasma, muscle and kidney AAA concentration under both normal and high protein diet, although this concentration remains normal in the liver. A major aromatic aminoaciduria and a smaller urinary loss of all substrates additionally transported by l‐type AA antiporter Lat2–4F2hc (Slc7a8) were revealed under a high protein diet. This suggests an epithelial transport defect as also shown by the accumulation of intravenously injected 123I‐2‐I‐l‐Phe in kidney and l‐[3H]Phe in ex vivo everted gut sac enterocytes. Taken together, these data indicate that the uniporter TAT1 is required to equilibrate the concentration of AAAs across specific membranes. For instance, it enables hepatocytes to function as a sink that controls the extracellular AAAs concentration. Additionally, it facilitates the release of AAAs across the basolateral membrane of small intestine and proximal kidney tubule epithelial cells, thereby allowing the efflux of other neutral AAs presumably via Lat2–4F2hc.

1 January 2014 in Endocrinology
Verified
Journal Article
Closed access
JMJulia Müller
Julia Müller
SMSteffen Mayerl
Steffen Mayerl
TVTheo J. Visser
Theo J. Visser
VDVeerle M. Darras
Veerle M. Darras
ABAnita Boelen
Anita Boelen
HHHeike Heuer
Heike Heuer
The monocarboxylate transporter Mct10 (Slc16a10; T-type amino acid transporter) facilitates the cellular transport of thyroid hormone (TH) and shows an overlapping expression with the well-established TH transporter Mct8. Because Mct8 deficiency is associated with distinct tissue-specific alterations in TH transport and metabolism, we speculated that Mct10 inactivation may compromise the tissue-specific TH homeostasis as well. However, analysis of Mct10 knockout (ko) mice revealed normal serum TH levels and tissue TH content in contrast to Mct8 ko mice that are characterized by high serum T3, low serum T4, decreased brain TH content, and increased tissue TH concentrations in the liver, kidneys, and thyroid gland. Surprisingly, mice deficient in both TH transporters (Mct10/Mct8 double knockout [dko] mice) showed normal serum T4 levels in the presence of elevated serum T3, indicating that the additional inactivation of Mct10 partially rescues the phenotype of Mct8 ko mice. As a consequence of the normal serum T4, brain T4 content and hypothalamic TRH expression were found to be normalized in the Mct10/Mct8 dko mice. In contrast, the hyperthyroid situation in liver, kidneys, and thyroid gland of Mct8 ko mice was even more severe in Mct10/Mct8 dko animals, suggesting that in these organs, both transporters contribute to the TH efflux. In summary, our data indicate that Mct10 indeed participates in tissue-specific TH transport and also contributes to the generation of the unusual serum TH profile characteristic for Mct8 deficiency.

16 January 2015 in The Journal of Physiology
Verified
Journal Article
Closed access
PDF file
AGAdriano Guetg
Adriano Guetg
LMLuca Mariotta
Luca Mariotta
LBLukas Bock
Lukas Bock
BHBrigitte Herzog
Brigitte Herzog
RFRalph Fingerhut
Ralph Fingerhut
FVFrançois Verrey
François Verrey